Bryan Cox Biography and Net Worth

Chief of Research of TriSalus Life Sciences

Dr. Bryan F. Cox has been the Chief of Research at TriSalus since June 2020.

Previously, Dr. Cox served as the Chief Executive Officer of Nephraegis Therapeutics, a biotechnology company, since November 2018. Prior to joining TriSalus, Dr. Cox served as a Consultant for CoPharm Global Consulting, a boutique consultancy focuses on providing guidance for biotechnology companies, from May 2013 to June 2020. Prior to that, Dr. Cox served as the Director of Integrative Pharmacology for Abbott Laboratories, a multinational medical devices and health care company, from 1996 to 2013. Dr. Cox has served on the board of directors for Nephraegis Therapeutics since November 2018.

Dr. Cox received his B.S. in Biological Sciences from North Carolina University and his Ph.D. in Pharmacology from the University of Iowa.

What is Bryan F. Cox's net worth?: The estimated net worth of Bryan F. Cox is at least $663.63 thousand as of March 16th, 2026. Dr. Cox owns 163,415 shares of TriSalus Life Sciences stock worth more than $663,628 as of June 22nd. This net worth estimate does not reflect any other investments that Dr. Cox may own. Learn More about Bryan F. Cox's net worth.
How do I contact Bryan F. Cox?: The corporate mailing address for Dr. Cox and other TriSalus Life Sciences executives is 6272 West 91st Avenue, Westminster, CO 80031, United States. TriSalus Life Sciences can also be reached via phone at 888-321-5212 and via email at [email protected]. Learn More on Bryan F. Cox's contact information.
Has Bryan F. Cox been buying or selling shares of TriSalus Life Sciences?: Bryan F. Cox has not been actively trading shares of TriSalus Life Sciences during the last ninety days. Most recently, Bryan F. Cox sold 579 shares of the business's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $4.12, for a transaction totalling $2,385.48. Following the completion of the sale, the insider now directly owns 163,415 shares of the company's stock, valued at $673,269.80. Learn More on Bryan F. Cox's trading history.
Are insiders buying or selling shares of TriSalus Life Sciences?: During the last twelve months, TriSalus Life Sciences insiders bought shares 5 times. They purchased a total of 719,682 shares worth more than $1,804,176.38. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 30,150 shares worth more than $119,849.35. The most recent insider tranaction occured on May, 15th when Director Mats Wahlstrom bought 60,000 shares worth more than $151,800.00. Insiders at TriSalus Life Sciences own 16.3% of the company. Learn More about insider trades at TriSalus Life Sciences.
Information on this page was last updated on 5/15/2026.

Bryan F. Cox Insider Trading History at TriSalus Life Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/16/2026	Sell	579	$4.12	$2,385.48	163,415
3/12/2026	Sell	1,467	$4.09	$6,000.03	163,994
3/11/2026	Sell	1,138	$4.13	$4,699.94	165,461
5/19/2025	Sell	4,764	$5.18	$24,677.52	119,415
10/5/2024	Sell	314	$4.44	$1,394.16	86,382

Bryan F. Cox Buying and Selling Activity at TriSalus Life Sciences

TriSalus Life Sciences Company Overview

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

Today's Range

Now: $4.13

$3.95

$4.16

50 Day Range

MA: $3.87

$2.52

$4.65

2 Week Range

Now: $4.13

$2.20

$7.95

Volume

102,456 shs

Average Volume

294,971 shs

Market Capitalization

$253.66 million

P/E Ratio

N/A

Dividend Yield